GvHD therapy with donor regulatory T cells (B07)

• Subject Area: Hematology, Oncology ; Immunology ; Clinical Immunology and Allergology
• Term: since 2018
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 324392634

We initially demonstrated that donor CD4+CD25+Foxp3+ regulatory T cells (Treg) prevent acute GvHD after MHC-mismatched ASCT. We then showed that they are also efficacious in the treatment of aGvHD and revealed that donor Treg rapidly adapt their phenotype and gene expression to the local environment, especially in the gastrointestinal tract. We now explore whether the microbiome contributes to organ-specific Treg adaptation, examine the mechanisms underlying their immune and tissue regenerating effects and determine whether their therapeutic efficacy can be enhanced by targeting tissue-specific or ubiquitous antigens.

• DFG Programme: CRC/Transregios
• Subproject of: TRR 221: Modulation of graft-versus-host and graft-versus-leukemia immune responses after allogeneic stem cell transplantation
• Applicant Institution: Universität Regensburg
• Project Heads: Professor Dr. Matthias Edinger; Privatdozentin Dr. Petra Hoffmann; Professor Dr. Michael Rehli